Ruge, T.; Larsson, A.; Lipcsey, M.; Tydén, J.; Johansson, J.; Eriksson, M.
A Comparison between Endostatin and Conventional Biomarkers on 30-Day Mortality and Renal Replacement Therapy in Unselected Intensive Care Patients. Biomedicines 2021, 9, 1603.
https://doi.org/10.3390/biomedicines9111603
AMA Style
Ruge T, Larsson A, Lipcsey M, Tydén J, Johansson J, Eriksson M.
A Comparison between Endostatin and Conventional Biomarkers on 30-Day Mortality and Renal Replacement Therapy in Unselected Intensive Care Patients. Biomedicines. 2021; 9(11):1603.
https://doi.org/10.3390/biomedicines9111603
Chicago/Turabian Style
Ruge, Toralph, Anders Larsson, Miklós Lipcsey, Jonas Tydén, Joakim Johansson, and Mats Eriksson.
2021. "A Comparison between Endostatin and Conventional Biomarkers on 30-Day Mortality and Renal Replacement Therapy in Unselected Intensive Care Patients" Biomedicines 9, no. 11: 1603.
https://doi.org/10.3390/biomedicines9111603
APA Style
Ruge, T., Larsson, A., Lipcsey, M., Tydén, J., Johansson, J., & Eriksson, M.
(2021). A Comparison between Endostatin and Conventional Biomarkers on 30-Day Mortality and Renal Replacement Therapy in Unselected Intensive Care Patients. Biomedicines, 9(11), 1603.
https://doi.org/10.3390/biomedicines9111603
